Tag: BioNTech

Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; ...

Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; ...

MAINZ, Germany, June 9, 2022 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) will welcome its African partners for the first time on the African continent and provide an update on ...

First quarter revenues of €6.4 billion1, net income of €3.7 billion and fully diluted earnings per share of €14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billionFirst-in-class ...

MAINZ, Germany, April 8, 2022 — BioNTech SE (Nasdaq: BNTX) today announced that it is one of the companies in Germany to be granted a pandemic preparedness contract by the ...

Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among ...

Collaboration leverages BioNTech’s multi-platform immunotherapy capabilities and Medigene’s T cell receptor (TCR) discovery platform to discover and develop innovative TCR immunotherapies against targets selected by BioNTechBioNTech to acquire preclinical PRAME ...

MAINZ, Germany, February 15, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will welcome project partners, among them official representatives, in Marburg to conduct a high-level meeting on ...

With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy of two 3 µg doses ...

First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years and older  NEW YORK and MAINZ, Germany, December 9, 2021 — Pfizer Inc. ...